Of note, small molecules that inhibit MDM2–p53 binding indeed show efficacy against p53 wild-type cancers, but most patients who have p53-mutant tumors may have intrinsic resistance to such p53-dependent MDM2 inhibitors. Here, MDM2 is linked to cancer.